

Atty Docket: ONYX1028-DIV  
Serial No. 10/054,435

In the claims,

Please amend the claims as follow:

Please cancel Claims 1, 31 and 32 and add new Claims 68 and 69

Claim 1. Cancelled

Claim 2 (Currently Amended). An isolated Rac-GEF, or a biologically-active fragment thereof, of claim 1, wherein said Rac-GEF, or said biologically-active fragment have has a guanine nucleotide exchange activity, a specific binding affinity for a guanine nucleotide depleted Rac, or a cellular oncogenic transforming activity.

Claim 3 (Currently Amended): An isolated Rac-GEF or a biologically-active fragment thereof of claim 1 which is of human.

Claim 4 (Currently Amended): An isolated Rac-GEF of claim 1 comprising amino acid 1 to amino acid 711, as set forth in Fig. 1 (SEQ. ID NO: 2) the amino acid sequence as set forth in SEQ. ID NO: 2

Claim 5 (Currently Amended): An isolated biologically-active fragment of Rac-GEF of claim 4 which comprises amino acids 273-605 of SEQ. ID NO: 2 .

Claim 6 (Currently Amended): An isolated Rac-GEF, or a biologically-active fragment thereof, of claim 1, which is substantially purified.

Claims 7 – 67 (Canceled):

Claim 68 (New): An isolated Rac-GEF encoded by a nucleic acid sequence which comprises at least 95% nucleotide sequence identity to the nucleotide sequence set forth in SEQ. ID. NO:1.

Claim 69 (New): An isolated Rac-GEF encoded by a nucleic acid sequence which

Atty Docket: ONYX1028-DIV  
Serial No. 10/054,435

comprises a nucleotide sequence which hybridizes, or whose nucleic acid complement hybridizes, under stringent conditions to the nucleotide sequence of SEQ.  
ID. NO: 1.

Sent By: Onyx Pharmaceuticals;

510-222-6767;

Oct-22-03 2:47PM;

Page 5

Atty Docket: ONYX1028-DIV  
Serial N . 10/054,435

Drawings

Applicants hereby submit 8 Sheets of formal drawings. These are the same drawings that can be found in the priority application (US Serial No.09/079,812, now United States Patent No. 6,340,575).